Teva Pharmaceutical (TEVA-N) Stock Predictions - Stockchase
WATCH LIST
257
Teva Pharmaceutical (TEVA-N)

ON STOCKCHASE SINCE Dec 2000

Patented and lower price generic drugs

biotechnology/pharmaceutical

Teva Pharmaceutical

TEVA-N

27 watching          
Join the Discussion

Teva Pharmaceutical (TEVA-N) SAVE Apr, 22, 2019, 12:26 pm

14.47 0.11 (0.77%)

About Teva Pharmaceutical (TEVA-N)

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. More at Wikipedia

What the experts are saying about TEVA-N



  • All
  • Filtered
Signal Opinion Expert
BUY
He'd buy it here. It won't go much lower than current levels based on the chart.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He'd buy it here. It won't go much lower than current levels based on the chart.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$15.780
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

February 13, 2019

They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$17.355
Owned Owned
No

BUY
Teva Pharmaceutical(TEVA-N) 

December 7, 2018

TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$19.410
Owned Owned
No

SELL
Teva Pharmaceutical(TEVA-N) 

December 6, 2018

A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$20.260
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

November 12, 2018

It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
It is a big generics play. It has been run fairly well over the years. They are reducing debt. It is okay. There is going to be a lot of selling pressure at the $30 level. Quarterly numbers are okay but there is so much out there that is better. He would use a health device and equipment ETF (IHI-N).
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$23.690
Owned Owned
Unknown

COMMENT
Teva Pharmaceutical(TEVA-N) 

October 1, 2018

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Generic drugs. Teva will benefit from an aging population and a growing push by governments to make drugs cheaper. However, Teva has been facing competition from other generic makers. In the long term, though, this will be a winner in this space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gavin Graham

Trustee, Pointbreak ETFs...

Price Price
$21.460
Owned Owned
Unknown

WATCH
Teva Pharmaceutical(TEVA-N) 

September 5, 2018

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$22.640
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

August 20, 2018

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

biotechnology/pharmaceutical
0 0 1 0 0
0 comments

He used to own it in the mid-2000's when they were positioned to benefit from new drugs coming off patent. This ended around 2011. Today, they have a lot of debt, and face declining drug prices.

biotechnology/pharmaceutical
0 0 1 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$25.650
Owned Owned
No

DON'T BUY

This became the largest generic drug manufacturer in the world who then took on debt to produce their own drugs. This has not worked out well. He would not be a holder of this, due to the competition in the space and the high debt levels. (Analysts’ price target is $21)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This became the largest generic drug manufacturer in the world who then took on debt to produce their own drugs. This has not worked out well. He would not be a holder of this, due to the competition in the space and the high debt levels. (Analysts’ price target is $21)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$23.870
Owned Owned
No

DON'T BUY

This company lost its identity as it evolved. Was it primarily a drug company or a marketer of generics? Its price dropped substantially after its main drug came off patent. Since then, the CEO left and the Board has reorganized. However, Teva still has a lot of debt. The debt load was moderate, but earnings have fallen so much that the debt has become relatively much more important, making this a risky investment. 16. 3M (MMM-N)(Doesn’t own)(Buy on weakness). This company did very well when value stocks were in favor, and has traded down. It is modestly priced compared to its historical levels, not cheap. This would be a good company to buy at a discount and hold for a long time.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This company lost its identity as it evolved. Was it primarily a drug company or a marketer of generics? Its price dropped substantially after its main drug came off patent. Since then, the CEO left and the Board has reorganized. However, Teva still has a lot of debt. The debt load was moderate, but earnings have fallen so much that the debt has become relatively much more important, making this a risky investment. 16. 3M (MMM-N)(Doesn’t own)(Buy on weakness). This company did very well when value stocks were in favor, and has traded down. It is modestly priced compared to its historical levels, not cheap. This would be a good company to buy at a discount and hold for a long time.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Darren Sissons

Vice Presi, Campbell Lee & Ross...

Price Price
$23.940
Owned Owned
No

DON'T BUY

Generic drug manufacturer. Too many operational issues on this company for them to buy it. Probably closer to the bottom but they would like to see more quarters of solid turn-around. They like other companies better in the space. (Analysts’ price target is $18.00)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Generic drug manufacturer. Too many operational issues on this company for them to buy it. Probably closer to the bottom but they would like to see more quarters of solid turn-around. They like other companies better in the space. (Analysts’ price target is $18.00)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jamie Murray

Head of re, Murray Wealth Group...

Price Price
$17.830
Owned Owned
No

BUY

An Israeli company that trades in the US. The largest generic pharmaceutical company in the world. They went through a difficult management period after its founder passed away. The important part of the generics is not really the molecule part (if you have smart people you can copy the molecules). The important part is the legal aspect. And here this company is very very strong. It is going to take a while to restructure the company, but they have a great franchise. Over a 3 to 5 years’ time horizon it is a great story to buy. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

An Israeli company that trades in the US. The largest generic pharmaceutical company in the world. They went through a difficult management period after its founder passed away. The important part of the generics is not really the molecule part (if you have smart people you can copy the molecules). The important part is the legal aspect. And here this company is very very strong. It is going to take a while to restructure the company, but they have a great franchise. Over a 3 to 5 years’ time horizon it is a great story to buy. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$17.670
Owned Owned
Yes

DON'T BUY

Teva  or Pfizer?  He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Teva  or Pfizer?  He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$17.600
Owned Owned
Unknown

BUY

He thinks the generic drug space is the cheapest sector out there.  Valeant impacted this space severely.  He holds this and so does Warren Buffet.  He likes this space, but bought it at a lower price.  He sees fair value at $25.11 – a 30% upside potential. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He thinks the generic drug space is the cheapest sector out there.  Valeant impacted this space severely.  He holds this and so does Warren Buffet.  He likes this space, but bought it at a lower price.  He sees fair value at $25.11 – a 30% upside potential. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$18.570
Owned Owned
Yes

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

February 13, 2018

Telepharmaceuticals is a scandal in Israel where he's just visited. Teva is the leader there. Their problems are deep and broad, from Teva's executive suite on down. Sold off his shares a while ago. Don't go near it. Need to get their ship in order.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Telepharmaceuticals is a scandal in Israel where he's just visited. Teva is the leader there. Their problems are deep and broad, from Teva's executive suite on down. Sold off his shares a while ago. Don't go near it. Need to get their ship in order.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$18.520
Owned Owned
Unknown

Showing 1 to 15 of 257 entries
Successfully Saved Company
Successfully Saved Company